AMENDMENT NO. 1 TO PROMISSORY NOTEPromissory Note • August 9th, 2017 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 1 TO PROMISSORY NOTE (this “Amendment”) is made as of June 12, 2017 by and among Celularity, Inc., a Delaware corporation (the “Borrower”) and Sorrento Therapeutics, Inc., a Delaware corporation (“Lender”).
FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 9th, 2017 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
THIS FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of April 13, 2017 (the “Fifth Amendment Effective Date”), is entered into by and among Sorrento Therapeutics, Inc., a Delaware corporation (“Parent”), Concortis Biosystems, Corp., a Delaware corporation, Ark Animal Health, Inc., a Delaware corporation, TNK Therapeutics, Inc., a Delaware corporation, Sorrento Biologics, Inc., a Delaware corporation, Scintilla Pharmaceuticals, Inc., a Delaware corporation, LA Cell, Inc., a Delaware corporation, SiniWest Holding Corp., a Delaware corporation, Levena Biopharma US, Inc., a Delaware corporation, BioServ Corporation (formerly known as Sorrento BioServices, Inc.), a Delaware corporation, Scilex Pharmaceuticals Inc., a Delaware corporation, SNAN Holdco LLC, a Delaware limited liability company and each of their Qualified Subsidiaries (together with “Parent” hereinafter collectively referred to as the “Borrower”), the several banks and other financial institutions o
CONSENT AND SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 9th, 2017 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • California
THIS CONSENT AND SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of April 27, 2017 (the “Sixth Amendment Effective Date”), is entered into by and among Sorrento Therapeutics, Inc., a Delaware corporation (“Parent”), Concortis Biosystems, Corp., a Delaware corporation, Ark Animal Health, Inc., a Delaware corporation, TNK Therapeutics, Inc., a Delaware corporation, Sorrento Biologics, Inc., a Delaware corporation, Scintilla Pharmaceuticals, Inc., a Delaware corporation, LA Cell, Inc., a Delaware corporation, SiniWest Holding Corp., a Delaware corporation, Levena Biopharma US, Inc., a Delaware corporation, BioServ Corporation (formerly known as Sorrento BioServices, Inc.), a Delaware corporation, Scilex Pharmaceuticals Inc., a Delaware corporation, SNAN Holdco LLC, a Delaware limited liability company and each of their Qualified Subsidiaries (together with “Parent” hereinafter collectively referred to as the “Borrower”), the several banks and other financial in
CONTRIBUTION AGREEMENTContribution Agreement • August 9th, 2017 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research • Delaware
This CONTRIBUTION AGREEMENT (this “Agreement”) is made as of June 12, 2017 (the “Agreement Date”), by and among Sorrento Therapeutics, Inc., a Delaware corporation (“Sorrento”), TNK Therapeutics, Inc., Delaware corporation and a majority owned subsidiary of Sorrento (the “TNK”), and Celularity, Inc., a Delaware corporation (“Celularity”).
AMENDMENT NO. 2 TO PROMISSORY NOTEPromissory Note • August 9th, 2017 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 2 TO PROMISSORY NOTE (this “Amendment”) is made as of June 30, 2017 by and among Celularity Inc., a Delaware corporation (the “Borrower”) and Sorrento Therapeutics, Inc., a Delaware corporation (“Lender”).
AMENDMENT NO. 1 TO CONTRIBUTION AGREEMENTContribution Agreement • August 9th, 2017 • Sorrento Therapeutics, Inc. • Services-commercial physical & biological research
THIS AMENDMENT NO. 1 TO CONTRIBUTION AGREEMENT (this “Amendment”) is made as of June 30, 2017 by and among Celularity Inc., a Delaware corporation (the “Celularity”) and TNK Therapeutics, Inc., a Delaware corporation (“TNK”).
